Blog Archives

Welcome New Members!

akrivisAkrivis is a privately held biopharmaceutical company based in Cambridge (Massachusetts) and committed to the early detection, diagnosis and treatment of serious and life-threatening diseases. Its patented Z-TECT™ and ADAPT™ technology platforms are in essence versatile, sequentially targeted, high payload nanocarrier systems that provide: (1) ultrasensitive in vitro detection; (2) high resolution in vivo imaging; and (3) sequentially targeted, efficient and specific delivery of high drug payloads to targeted biomarkers with improved efficacy and safety. Website

bionique-logoBionique Testing Laboratories is a leading global provider of mycoplasma testing services. For over 25 years, Bionique has been a trusted partner to the pharma, biotech, research, and reagent supplier industries. Website

bioscikinBioSciKin (BSK) Pharma Pioneers is headquartered in Nanjing, China and has two major sites in Shanghai and Tianjin. Its mission is to partner with global biotech companies and academic institutions to develop innovative therapeutics and healthcare products in China in parallel with partners’ global development plans. Successful partnership is supported by BSK venture as well as pre-clinical and clinical development capabilities derived from Simcere Pharmaceutical Group’s years of experience. Website

Hemeon Medical

Medical device company based in Scituate, MA. Website

Kiniksa-Logo-height-40.pngKiniksa Pharmaceuticals is a privately held biotechnology company focused on developing and delivering therapeutics to patients with devastating diseases and unmet medical needs. The company has an experienced management team, significant funding and a clear vision of building a global, generational company. Website

KSQ Therapeutics

KSQ Therapeutics, Inc. is a functional genomics company. We have developed a novel genetics tool that allows us to screen the human genome to uncover information on specific diseases. We utilize this knowledge to target drugs for treatment of these diseases. Website

optimal wealthOptimal Wealth is a Financial Planning boutique firm that specializes in meeting the needs of the Biotech community. Our mission is to help families create and preserve wealth and income streams through sound financial strategies. Our team uses a highly consultative, tailored approach. Our staff are experts in Financial Planning, Risk Management, Wealth Management, Trust & Estates and Philanthropic Planning. We work closely with each client’s other advisors and our extended network to enable integrated management of your financial affairs. Website

proskauerProskauer Rose LLP is a full-service international law firm providing comprehensive, strategic counseling to clients in the biotechnology industry. Our clients include start-ups, established companies, universities, university spin-outs, and private equity funds. Website

stat news logoSTAT delivers fast, deep, and tough-minded journalism. We take you inside science labs and hospitals, biotech boardrooms, and political backrooms. We dissect crucial discoveries. We examine controversies and puncture hype. We hold individuals and institutions accountable. We introduce you to the power brokers and personalities who are driving a revolution in human health. These are the stories that matter to us all. Website

vetter logoVetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Collaborating with pharma/biotech clients worldwide, Vetter supports products from preclinical development through global market supply. Through its U.S. and European facilities, Vetter Development Service provides state-of-the-art support for early-stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. The company offers state-of-the-art technology and innovative processes to promote product quality and maximize API yield. Website


VL34 is an early-stage startup in Cambridge, MA using cutting-edge molecular techniques to help create a novel category of fertility treatment. VL34 was founded by VentureLabs, a unit of Flagship Ventures which has launched over 25 breakthrough companies including Seres Therapeutics, Symbiota, Pronutria, and Moderna Therapeutics. Website

withum smith and brownWith a long-standing reputation within the industry, WithumSmith+Brown partners with Life Science organizations to help navigate the business issues unique to their industry. Our Life Science specialists work with many pharmaceutical, biotech and medical device companies, as well as other related businesses within the industry. Whether you need additional private or public capital, assistance with SEC matters, internal operating efficiencies or intellectual property royalties, WS+B has the industry experience and expertise to help you achieve your objectives. Website



Top 10 Tips: How to Impress the Biotech Press

On Thursday November 12th, MassBio hosted Meet the Press with a panel of some of the most influential journalists in healthcare and biotech including:

  • Jessica Bartlett, Health Care Reporter, Boston Business Journal
  • Doni Bloomfield, Biotech Reporter, Bloomberg News
  • Stephanie Simon, Managing Editor of News, STAT
  • Luke Timmerman, Founder & Editor, The Timmerman Report

The reporters shared insider tips to help the audience learn how to get their stories covered.


We’ve captured the top 10 tips in case you missed the event:

  1. Develop relationships with reporters and be sure to make meetings worth while.
  2. When pitching your story, look over a reporter’s past headlines to learn their style and the topics that interest them most.
  3. Preferred way to receive a pitch? Email!
  4. Press releases aren’t dead, but they are more useful as background so don’t obsess over wording. Write a short summary in your email and explain why this would be a great story.
  5. Originality and timeliness are key elements of a good pitch, and exclusives are ideal.
  6. When possible, connect reporters to the “decision-makers” at your company even if it is off the record.
  7. On drug pricing: It’s not going away so don’t avoid it. Focus on conveying the value of medicine and always be transparent.
  8. Respond to questions promptly and be willing to jump on the phone to explain technical elements.
  9. See an error? Call immediately! The reporter wants to know and is happy to make a correction. (Just remember an error is something that is factually incorrect, not a wording preference.)
  10. Data is valuable. Share it!

Happy pitching! We hope to see your story in the news soon!

Top 5 News: 10/31-11/6

Top 5 logo1) Globe’s owner unveils site focused on health, life-sciences Boston Globe, 11/4/2015
Boston Globe owner John W. Henry on Wednesday will formally launch STAT, an online health and life-sciences publication that will cover stories across the country.

2) With Spark moving in, the Bay State is becoming the world’s gene therapy hub BBJ, 11/4/2015
Spark Therapeutics may not be a well-known company the same way that Baxter International, Shire and AbbVie are, but the announcement this morning that the Philadelphia-based firm is opening a local office is at least as important for the local biotech cluster as those big pharma giants’ expansion here.

3) Shire ramps up buying spree with $5.9 billion deal for Dyax Boston Globe, 11/2/2015
On Monday, Shire unveiled a $5.9 billion agreement to buy Burlington’s Dyax Corp., which is developing a promising drug to treat a rare disease called hereditary angioendema.

4) Medical first: Gene-editing tool used to treat girl’s cancer – STAT News,11/5/2015
In what’s being billed as a medical first, scientists in London have used a new kind of biological scissors in a last-ditch effort to cure a child with otherwise untreatable leukemia. They edited genes in immune cells to make them hunt down and destroy the malignant blood cells that threatened the year-old girl’s life.

5) Myths And Facts About Specialty Drugs – Forbes, 11/3/2015
The ongoing debate over specialty drugs — reflecting conflicting motives of buyers and sellers — neglects important insights about the impact of these new technologies, their value to society, and the economics of medical R&D. We here disentangle the facts from the myths surrounding these products.

Meet the Best of the Biotech Press at MassBio!

John KingBy: John King, Head of U.S. Gaucher and MPS Marketing at Genzyme

On Thursday, November 12th, MassBio is presenting a special Meet the Press event to bring members of the biotech community new insights about how top healthcare reporters cover both company news and the issues that affect our industry. The program will be held from 8:00 AM – 10:00 AM on Thursday, November 12, at MassBio, 300 Technology Sq., 8th Floor, Cambridge, MA.

Whether you work at a biotech or pharma company or on the agency side in marketing or PR, you will not want to miss it!

Participants in this program include four of the most influential reporters covering biotechnology and healthcare today:

  • Jessica Bartlett, Health Care Reporter, Boston Business Journal
  • Doni Bloomfield, Biotech Reporter, Bloomberg News
  • Stephanie Simon, Managing Editor of News, Stat, Boston Globe
  • Luke Timmerman, Founder & Editor, The Timmerman Report

The program will be moderated by Bo Piela, VP of Corporate Communications at Genzyme, a Sanofi Company. And I am very plea honored that I will have the opportunity to welcome everyone on behalf of MassBio.

Panelists will discuss:

  • How they decide to cover news related to new products, research and regulatory milestones, and issues associated with product safety, pricing, and regulation.
  • Which products and issues are not considered newsworthy, and why.
  • Topics in drug development and healthcare that are “hot” right now.
  • Trends they are watching for coverage next year.
  • How they use press releases, infographics, marketing materials, web sites and other resources from biotechnology companies.

Following the panel discussion, there will be a chance to meet one-on-one with the reporters for more in-depth questioning and additional information. Given how important media coverage has become in biotechnology, you will not want to miss this chance to connect with these experts!

The event is only one week away!

Register now!